Definitive Contract 36C25220C0082

This $507,000 firm-fixed-price purchase order was awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, to Deutsches Krebsforschungszentrum (DKFZ), a German non-profit organization focused on cancer research. The contract requires DKFZ to test no more than 13,000 samples previously collected in the Anchor Trial using a multiplex serology assay of up to 41 antigens. The work is to be performed at DKFZ's facilities in Heidelberg, Germany, with...

This is a $224,715.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is for a study titled "MERKELOMV-AP STUDY (BABOONS)" with a completion date of September 2, 2022. The contract does not have a set-aside designation. MD Anderson Cancer Center is a comprehensive cancer treatment and research...

This is a Cost Plus Fixed Fee delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Battelle Memorial Institute, a non-profit organization and manufacturer of goods. The contract is for an exploratory toxicology study in dogs of an MCL-1 inhibitor drug being developed for cancer and other diseases. The contract has a potential value of $116,039 and a completion date of June 30, 2021. It is a task...

This is a federal contract award from the National Cancer Institute, a civilian agency, to Istituto Oncologico Veneto in Italy. The $99,150.00 Firm Fixed Price contract is for the review of tumor, adjacent normal, and nevus remnant samples, as well as DNA extraction from melanoma and other skin lesions collected from Mediterranean populations. The contract does not have a set-aside designation. No subcontractors are mentioned. The contract supports the National Cancer Institute's research and...

This is a delivery order awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., by the National Cancer Institute (NCI). The $3,323,184.00 cost-plus-fixed-fee contract is for longitudinal studies of dogs with cancer as a comparative oncology model. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for NCI, providing a range of biomedical research and facilities support services. This contract has no set-aside...

This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Experimental Pathology Laboratories, Inc. (EPL) to provide histopathology services to support 5 efficacy studies for viruses with pandemic potential. The contract has a ceiling value of $803,683.20 and a period of performance from September 25, 2024, to September 24, 2025, with options for additional studies. EPL, a for-profit, employee-owned contract...

This firm fixed-price purchase order for $86,631 was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Labcorp Early Development Laboratories Inc. to perform 60-month stability testing of two lots of LMB-100 drug product. LMB-100 is an anti-mesothelin immunotoxin under clinical trials for certain cancers. The prime contractor Labcorp will conduct a battery of assays to ensure the identity, potency, and safety of the drug product...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by a U.S. government agency to Milagen, Inc., a for-profit organization, for a project titled "From Animal Model of Prostate Cancer to Biomarkers of Human Prostate Cancer." The contract has a potential value of $2,991,916.00 and was awarded on September 16, 2005, with a completion date of September 15, 2007. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, and the place of...

<p>This is a definitive federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Mansfield Medical Research on September 15, 1992. The contract has a ceiling value of $443,137,907.91 and is for the PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL. The contract is a cost-sharing agreement and does not have a set-aside designation. The contract is scheduled to be completed by March 31, 2012. The place of performance is Marshfield, Wisconsin.</p>

This is a definitive contract award by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to Experimental Pathology Laboratories, Inc. (EPL) for &quot;The Registry of Tumors in Lower Animals&quot; project. The $14,573,033.00 cost-plus-fixed-fee contract has a period of performance through September 29, 2007. EPL, a for-profit Subchapter S corporation registered in SAM.gov, is a contract research organization specializing in toxicology pathology...